182 related articles for article (PubMed ID: 29670141)
41. Nomogram Predicting Survival After Recurrence in Patients With Stage I to III Colon Cancer: A Nationwide Multicenter Study.
Kawai K; Nozawa H; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Sugihara K; Watanabe T
Dis Colon Rectum; 2018 Sep; 61(9):1053-1062. PubMed ID: 30086054
[TBL] [Abstract][Full Text] [Related]
42. MiRNA-362-3p induces cell cycle arrest through targeting of E2F1, USF2 and PTPN1 and is associated with recurrence of colorectal cancer.
Christensen LL; Tobiasen H; Holm A; Schepeler T; Ostenfeld MS; Thorsen K; Rasmussen MH; Birkenkamp-Demtroeder K; Sieber OM; Gibbs P; Lubinski J; Lamy P; ; Laurberg S; Oster B; Hansen KQ; Hagemann-Madsen R; Byskov K; Ørntoft TF; Andersen CL
Int J Cancer; 2013 Jul; 133(1):67-78. PubMed ID: 23280316
[TBL] [Abstract][Full Text] [Related]
43. Genome‑scale analysis to identify potential prognostic microRNA biomarkers for predicting overall survival in patients with colon adenocarcinoma.
Wei HT; Guo EN; Liao XW; Chen LS; Wang JL; Ni M; Liang C
Oncol Rep; 2018 Oct; 40(4):1947-1958. PubMed ID: 30066920
[TBL] [Abstract][Full Text] [Related]
44. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value of early relapse in colon cancer.
Dai W; Feng Y; Mo S; Xiang W; Li Q; Wang R; Xu Y; Cai G
Carcinogenesis; 2018 Oct; 39(10):1235-1244. PubMed ID: 29982331
[TBL] [Abstract][Full Text] [Related]
45. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma.
Schetter AJ; Nguyen GH; Bowman ED; Mathé EA; Yuen ST; Hawkes JE; Croce CM; Leung SY; Harris CC
Clin Cancer Res; 2009 Sep; 15(18):5878-87. PubMed ID: 19737943
[TBL] [Abstract][Full Text] [Related]
46. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy.
Manceau G; Imbeaud S; Thiébaut R; Liébaert F; Fontaine K; Rousseau F; Génin B; Le Corre D; Didelot A; Vincent M; Bachet JB; Chibaudel B; Bouché O; Landi B; Bibeau F; Leroy K; Penault-Llorca F; Van Laethem JL; Demetter P; Tejpar S; Rossi S; Mosakhani N; Osterlund P; Ristamäki R; Sarhadi V; Knuutila S; Boige V; André T; Laurent-Puig P
Clin Cancer Res; 2014 Jun; 20(12):3338-47. PubMed ID: 24771647
[TBL] [Abstract][Full Text] [Related]
47. A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis.
Hanniford D; Zhong J; Koetz L; Gaziel-Sovran A; Lackaye DJ; Shang S; Pavlick A; Shapiro R; Berman R; Darvishian F; Shao Y; Osman I; Hernando E
Clin Cancer Res; 2015 Nov; 21(21):4903-12. PubMed ID: 26089374
[TBL] [Abstract][Full Text] [Related]
48. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
Pagès F; Mlecnik B; Marliot F; Bindea G; Ou FS; Bifulco C; Lugli A; Zlobec I; Rau TT; Berger MD; Nagtegaal ID; Vink-Börger E; Hartmann A; Geppert C; Kolwelter J; Merkel S; Grützmann R; Van den Eynde M; Jouret-Mourin A; Kartheuser A; Léonard D; Remue C; Wang JY; Bavi P; Roehrl MHA; Ohashi PS; Nguyen LT; Han S; MacGregor HL; Hafezi-Bakhtiari S; Wouters BG; Masucci GV; Andersson EK; Zavadova E; Vocka M; Spacek J; Petruzelka L; Konopasek B; Dundr P; Skalova H; Nemejcova K; Botti G; Tatangelo F; Delrio P; Ciliberto G; Maio M; Laghi L; Grizzi F; Fredriksen T; Buttard B; Angelova M; Vasaturo A; Maby P; Church SE; Angell HK; Lafontaine L; Bruni D; El Sissy C; Haicheur N; Kirilovsky A; Berger A; Lagorce C; Meyers JP; Paustian C; Feng Z; Ballesteros-Merino C; Dijkstra J; van de Water C; van Lent-van Vliet S; Knijn N; Mușină AM; Scripcariu DV; Popivanova B; Xu M; Fujita T; Hazama S; Suzuki N; Nagano H; Okuno K; Torigoe T; Sato N; Furuhata T; Takemasa I; Itoh K; Patel PS; Vora HH; Shah B; Patel JB; Rajvik KN; Pandya SJ; Shukla SN; Wang Y; Zhang G; Kawakami Y; Marincola FM; Ascierto PA; Sargent DJ; Fox BA; Galon J
Lancet; 2018 May; 391(10135):2128-2139. PubMed ID: 29754777
[TBL] [Abstract][Full Text] [Related]
49. Tumour budding is a reproducible index for risk stratification of patients with stage II colon cancer.
Lai YH; Wu LC; Li PS; Wu WH; Yang SB; Xia P; He XX; Xiao LB
Colorectal Dis; 2014 Apr; 16(4):259-64. PubMed ID: 24118729
[TBL] [Abstract][Full Text] [Related]
50. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
51. Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort.
Hansen TF; Kjær-Frifeldt S; Christensen RD; Morgenthaler S; Blondal T; Lindebjerg J; Sørensen FB; Jakobsen A
Br J Cancer; 2014 Sep; 111(7):1285-92. PubMed ID: 25051407
[TBL] [Abstract][Full Text] [Related]
52. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.
Dienstmann R; Mason MJ; Sinicrope FA; Phipps AI; Tejpar S; Nesbakken A; Danielsen SA; Sveen A; Buchanan DD; Clendenning M; Rosty C; Bot B; Alberts SR; Milburn Jessup J; Lothe RA; Delorenzi M; Newcomb PA; Sargent D; Guinney J
Ann Oncol; 2017 May; 28(5):1023-1031. PubMed ID: 28453697
[TBL] [Abstract][Full Text] [Related]
53. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
54. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer.
Krishnan P; Ghosh S; Wang B; Li D; Narasimhan A; Berendt R; Graham K; Mackey JR; Kovalchuk O; Damaraju S
BMC Genomics; 2015 Sep; 16():735. PubMed ID: 26416693
[TBL] [Abstract][Full Text] [Related]
55. A Competing Endogenous RNA Network Reveals Novel Potential lncRNA, miRNA, and mRNA Biomarkers in the Prognosis of Human Colon Adenocarcinoma.
Wang WJ; Li HT; Yu JP; Han XP; Xu ZP; Li YM; Jiao ZY; Liu HB
J Surg Res; 2019 Mar; 235():22-33. PubMed ID: 30691798
[TBL] [Abstract][Full Text] [Related]
56. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
57. Identification of non-invasive biomarkers for chronic atrophic gastritis from serum exosomal microRNAs.
Liu H; Li PW; Yang WQ; Mi H; Pan JL; Huang YC; Hou ZK; Hou QK; Luo Q; Liu FB
BMC Cancer; 2019 Feb; 19(1):129. PubMed ID: 30736753
[TBL] [Abstract][Full Text] [Related]
58. A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.
Du F; Yuan P; Zhao ZT; Yang Z; Wang T; Zhao JD; Luo Y; Ma F; Wang JY; Fan Y; Cai RG; Zhang P; Li Q; Song YM; Xu BH
Sci Rep; 2016 Sep; 6():33825. PubMed ID: 27650797
[TBL] [Abstract][Full Text] [Related]
59. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
[TBL] [Abstract][Full Text] [Related]
60. Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma.
Chen L; Chu F; Cao Y; Shao J; Wang F
Tumour Biol; 2015 Sep; 36(10):7439-47. PubMed ID: 25903466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
